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Abstract In the treatment of pulmonary embolism (PE)
two groups of patients are traditionally identified, namely
the hemodynamically stable and instable groups. However,
in the large group of normotensive patients with PE, there
seems to be a subgroup of patients with an increased risk of
an adverse outcome, which might benefit from more
aggressive therapy than the current standard therapy with
anticoagulants. Risk stratification is a commonly used
method to define subgroups of patients with either a high
or low risk of an adverse outcome. In this review the
clinical parameters and biomarkers of myocardial injury
and right ventricular dysfunction (RVD) that have been
suggested to play an important role in the risk stratification
of PE are described first. Secondly, the use of more direct
imaging techniques like echocardiography and CT in the
assessment of RVD are discussed, followed by a brief
outline of new imaging techniques. Finally, two risk
stratification models are proposed, combining the markers
of RVD with cardiac biomarkers of ischemia to define
whether patients should be admitted to the intensive care
unit (ICU) and/or be given thrombolysis, admitted to the
medical ward, or be safely treated at home with anticoag-
ulant therapy.
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Introduction
Pulmonary embolism (PE) is a common and potentially
fatal cardiovascular disorder. The clinical presentation of
acute PE reveals a wide spectrum, ranging from mild
dyspnea to cardiac arrest. The short-term mortality of PE
also varies widely, ranging from less than 1% in hemody-
namically stable patients with non-massive PE and no signs
of right heart overload to over 90% in patients who present
with cardiorespiratory arrest [1].
In the treatment of PE two groups of patients are
traditionally identified. Given the high mortality risk in
hemodynamically unstable patients, aggressive therapies
such as thrombolytics, inotropic vasoactive drugs, embo-
lectomy, or thrombus fragmentation are indicated [2–4]. In
the large group of normotensive patients, anticoagulant
treatment is started as the risk of an adverse event due to
more aggressive treatment is considered higher than the
relatively low risk of PE-related death.
Recent studies have demonstrated that up to 55% of
normotensive patients with PE have asymptomatic right
ventricular dysfunction (RVD). These normotensive
patients with RVD have a higher risk of an adverse
outcome with an estimated 30-day mortality directly related
to PE between 3 and 10% [5], and an absolute increase in
early PE-related mortality of 4–5% [6], or a doubling of the
risk of all-cause death during 3-month follow-up [7]. This
is significantly higher than the early PE-related mortality in
the overall group of normotensive patients (1–7%) [8, 9]. It
has been debated that normotensive PE patients with RVD
might benefit from thrombolytic therapy [10, 11]. In
contrast, there may also be a subgroup of hemodynamically
stable patients without RVD that have a very low risk of
adverse outcomes and in whom early hospital discharge or
even home treatment may be considered.
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DOI 10.1007/s13244-011-0123-2Risk stratification is a frequently used method to identify
subgroups of patients that may benefit from different
diagnostic or treatment methods based on a different risk
profile. In this review, we discuss the parameters that are
currently proposed for prognostic stratification of patients
with acute PE. These parameters can, from a practical point
of view, be classified into three groups: the first group
consists of clinical parameters that can be immediately
obtained at bedside, mainly to assess hemodynamic status
and distinguish high-risk from non-high-risk PE patients.
The second group contains biomarkers of myocardial
injury, and finally, markers of RVD make up the third
group. Both cardiac biomarkers and markers of RVD can be
used to further stratify non-high-risk PE patients into
intermediate- and low-risk subgroups [3]. Based on the
literature currently available, a potential risk stratification
strategy is proposed. The benefit of this and other risk
stratification strategies, however, is currently under inves-
tigation and has to be demonstrated in prognostic studies
before implementation in clinical practice can be recom-
mended. Before we discuss the parameters that are
currently considered for clinical risk stratification of
patients with PE, we will first expound the pathophysiology
of PE to understand the broad clinical spectrum of PE.
Pathophysiology of PE
PE can lead to RVD and eventually cardiac failure due to
several mechanisms (Fig. 1). At first, PE leads to
pulmonary artery (PA) obstruction, which increases the
pulmonary vascular resistance. This, in turn, results in an
increase in right ventricular (RV) afterload, causing RVD,
together resulting in a decreased RV output. At the same
time the clot induces the release of neurohumoral sub-
stances stimulating arterial vasoconstriction and hypox-
emia, thereby increasing pulmonary vascular resistance and
RVafterload. Eventually, when RVD is the result of the PE,
an increase in RV volume and RV dilatation can be the next
step. Because the heart is contained within the pericardium,
an increase in RV volume also leads to a shift of the
interventricular septum to the left, decreasing the left
ventricular (LV) preload and output. In the end, this leads
to a decreased cardiac output.
As a consequence of the increased RV afterload, the
increased RV wall tension, and increased oxygen demand of
the RV, the coronary perfusion of the RV will decrease,
leading to ischemia. This in turn stimulates further RVD.
Finally, pre-existent cardiopulmonary disease further con-
tributes to the severity of the hemodynamic alterations.
The large differences in outcome in PE are assumed to be
related both to the embolus burden and the cardiopulmonary
status [12]. Wood et al. proposed a relationship between the
severity of the embolic event, characterized by both the
embolus size and the cardiopulmonary function, and the
mortality in patients with PE. They state that the combination
of the embolus size and the cardiopulmonary function
leading to shock seems to be associated with a mortality of
approximately 30%. Furthermore, a slightly further increase
in severity would lead to cardiac arrest, having a mortality of
at least 70%, and eventually lead to sudden death. However,
it remains unclear which exact combinations of embolus load
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Fig. 1 Pathophysiology of pul-
monary embolism. Due to ob-
struction of the pulmonary
vascular bed, increased vascular
resistance, and increased RV
afterload, PE can lead to RVD.
RVD can have several conse-
quences. First, it can decrease
RV output. Second, RVD may
result in a decrease of LV pre-
load and output, caused by an
increased RV volume and dila-
tation, eventually leading to de-
creased cardiac output. Finally,
RVD can cause decreased coro-
nary perfusion, leading to is-
chemia, which in turn results in
a further increase of RVD. RV =
right ventricle, PE = pulmonary
embolism, RVD = right ventric-
ular dysfunction, LV = left ven-
tricle, PA = pulmonary artery
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instability and consequently an exponential increase in
mortality rates in normotensive patients with PE. Therefore,
it might be of interest to know if there are any predictors that
account for this rapid increase in mortality. It is thought that
in the group of normotensive patients RVD is an important
indicator of an increase in mortality [12].
Clinical parameters
The most important clinical prognostic factors for PE are
hypotension and shock [13]. As mentioned before, these
patients with hypotension and shock are at high risk, having
a short-term mortality of approximately 30% [12]. Because
of hemodynamic instability, computed tomography (CT),
pulmonary angiography or scintigraphy usually is not
performed in the immediate diagnostic workup, and the
diagnosis is usually made on the basis of high clinical
suspicion and signs of RV failure on echocardiography [3].
However, clinical factors may not only be useful for the
initial identification of potentially fatal PE patients, but
some of them can also be used to identify patients at the
other end of the clinical spectrum, namely those that are at
low-risk of an adverse outcome. A commonly used
prognostic model is the Pulmonary Embolism Severity
Index (PESI) based on 11 patient factors that are all
independently associated with short-term mortality and
non-fatal adverse outcomes (Table 1)[ 7, 14]. The PESI
was developed to identify low-risk patients who may be
potential candidates for outpatient treatment or early
hospital discharge.
Cardiac biomarkers
Cardiac biomarkers are currently used in the diagnostic
workup of acute chest pain and dyspnea. However, there is
increasing evidence that they may also be relevant in PE
risk stratification [15]. Cardiac biomarkers can be sub-
divided into two major groups: markers of RVD, particu-
larly brain natriuretic peptides, and markers of myocardial
injury, of which troponins are the most important
representatives.
Brain natriuretic peptides
Brain natriuretic peptides (BNP) or N-terminal proBNP (NT-
proBNP) are cardiac biomarkers released with increased
myocardial stretch. There is increasing evidence that the
BNP andNT-proBNPlevelsare directlyrelatedtothe severity
ofRVD[16, 17]. In a systematic review, Sanchez et al. found
a relative risk for predicting 30-day mortality of 9.5 for BNP
and 5.7 for pro-BNP in patients with proven PE [18].
Although the negative predictive value (NPV) of BNP/NT-
proBNP is very high (94–100%), the positive predictive
value (PPV) is rather low (12–26%) [3]. Consequently, these
biomarkers seem especially useful to identify patients with
PE who are at low risk of an adverse outcome.
Cardiac troponins
Elevated levels of troponins (ei t h e rIo rT )a r ef o u n di np a t i e n t s
with acute myocardial infarction due to injury of myocardial
cells [19]. Troponin-T is released when RVischemia is present.
Elevated troponin T levels were found in 32% of patients with
massive and moderate PE, but not in patients with mild PE
[20]. Furthermore, Sanchez et al. revealed a strong relation-
ship between elevated troponin T levels and 30-day mortality
[18]. Although elevated troponin levels are associated with
increased early mortality, the PPV is low (12–44%) [3]. In
contrast, normal troponin T levels revealed a high NPVof 99–
100% for both fatal and non-fatal adverse events [3]. Troponin
levels may therefore be useful either as a marker of low risk of
an adverse outcome when they are normal or as a marker of
high risk when they are elevated.
Other biomarkers
The latest biomarkers studied include the fatty acid binding
proteins (FABPs), which have been proposed as more
Table 1 Pulmonary embolism severity index
Predictors Score
Age Age, in years
Male sex 10
Cancer 30
Heart failure 10
Chronic lung disease 10
Pulse ≥110/min 20
Systolic blood pressure <100 mmHg 30
Respiratory rate ≥30/min 20
Temperature <36° 20
Altered mental status* 60
Arterial oxygen saturation <90%** 20
The pulmonary embolism severity index (PESI) consists of 11
indepent predictors of short-term mortality in patients with acute
pulmonary embolism [14]. By adding the patient’s age in years and the
applicable predictor, a total score is obtained. Based on this total score
patients are classified into one of the five risk classes: ≤ 65 class I, 66–
85 class II, 86–105 class III, 106–125 class IV, >125 class V. Classes I
an II are defined as low risk; classes III–V are defined as higher risk
*Defined as disorientation, lethargy, stupor or coma
**With and without the administration of supplemental oxygen
Insights Imaging (2011) 2:705–715 707sensitive markers of myocardial injury than troponin T and
NT-proBNP [21], and are associated with several adverse
outcomes, including shock, intubation and cardiopulmonary
resuscitation [22]. D-dimer is a biomarker of fibrinolysis
and inflammation, and is elevated in the presence of an
acute clot. In patients with PE, plasma D-dimer levels were
found to be higher in patients who died of PE than in those
who survived [23]. Growth differentiation factor 15 (GDF-
15) is a cytokine released in the heart in response to
ischemia or pressure overload. In patients with acute PE,
GDF-15 was an independent predictor of a complicated 30-
day course and of long-term mortality [24].
Although all these relatively new biomarkers can be
considered of additional value in relation to the prognosis
of PE, they have not yet been evaluated in prospective
studies, and their potential role as an independent predictor
of adverse outcome in PE patients still needs to be
determined.
Imaging assessment in RVD
As mentioned before, RVD is an important prognostic
indicator in patients with PE. Whereas cardiac biomarkers
are an indirect parameter of RVD, it can be more directly
assessed using imaging methods such as echocardiography
and computed tomography angiography (CTA).
Echocardiography
Echocardiography is widely used for the assessment of
RVD in patients with PE [25]. Although a generally
accepted definition of RVD in echocardiography is lacking
[3], echocardiographic findings that are helpful and
frequently used in the diagnosis of RVD are: RV dilatation,
RV free wall hypokinesis, paradoxal septal wall motion, PA
dilatation, a systolic pressure gradient between RV and LV
>30 mmHg, and PA flow acceleration time <80 ms [10, 18,
26, 27]. RV dilatation as a marker of RVD is mostly
determined by the ratio of RVend-diastolic diameter/LVend-
diastolic diameter, with a ratio ≥0.6–1.0 considered abnor-
mal according to several authors [18]. In the International
Cooperative Pulmonary Embolism Registry (ICOPER) RV
hypokinesis was revealed to be an independent predictor of
30-day mortality in normotensive patients (hazard ratio
1.94, 95% CI 1.23–3.06) [28]. It was already found to
double the risk of death within the ensuing 3 months in a
study published by the same group [7]. In a retrospective
analysis by Sukija et al. paradoxal septal wall motion
increased the in-hospital mortality in patients with acute PE
[29]. The other indirect signs of RVD, i.e., dilatation of the
right PA, a systolic pressure gradient between the RV and
right atrium (RA) >30 mmHg, and a PA flow acceleration
time <80 ms, have also been used by several authors in
defining RVD [15, 26, 30–32].
Computed tomography
While pulmonary angiography has long been considered
the gold standard in the diagnosis of PE, nowadays
computed tomography angiography (CTA) is the first
imaging method of choice in the workup of patients with
suspected PE [33]. Besides diagnosing PE by direct
visualization of the thrombus, CTA can also be helpful in
the risk stratification of patients with PE. As with
echocardiography the RV/LV diameter ratio as a parameter
of RVD can easily be assessed on CT [3]. On axial views a
RV/LV ratio ≥0.9–1.5 has been shown to be directly
correlated with RVD and adverse outcome [34]. The PPV
is low (10%), but a RV/LV ratio <1 has a high NPV (100%)
[35]. Two examples of patients with extensive PE and RVD
are given in Figs. 2 and 3. One patient suffered cardiac
arrest and died shortly after; the other patient was
hemodynamically stable at presentation.
The additional value of a four-chamber view in the
assessment of the RV/LV ratio has been mentioned, but
these data are inconclusive [36–39]. These contradicting
results, together with the necessity of additional software
and extra time in order to obtain a RV/LV ratio on four-
chamber view, make assessment on the axial views the
preferred method these days.
When the results of studies on the prognostic role of
RVD assessed on echocardiography are taken together with
those assessed on CT, the relative risk of RVD for
predicting death is 2.4 [18]. Furthermore, RVD may also
predict poor pulmonary clot resolution at 6 months, and a
higher incidence or venous thromboembolism (VTE)
recurrence was demonstrated when RVD was present [40].
Controversial markers of RVD
Several other parameters in predicting RVD on CTA have
been mentioned, such as dilatation of the superior vena
cava (SVC) and azygos vein (AV), resulting from an acute
increase in blood volume and pressure in the RA. A study
of Ghaye et al. in patients with severe PE revealed
significantly different diameters of the SVC and AV
between survivors and non-survivors, but only the AV
diameter was found to predict mortality [41]. Another study
not only demonstrated the AV diameter as a predictor of
mortality in acute PE, but the SVC diameter was also
significantly correlated to mortality [42]. A more recent
publication showed the AV diameter to be significantly
increased in the severe PE group compared with the non-
severe PE group, whereas no statistically significant
difference in diameter of the SVC was present [43]. The
708 Insights Imaging (2011) 2:705–715dilatation of the AV has so far been revealing the strongest
correlation with adverse outcome in PE patients, but
whether there is an additional value as compared to other
independent predictors of adverse outcome in PE has not
been determined yet.
Because the increase in blood volume and pressure in the
RA and eventually in the RV can also cause backflow in the
inferior vena cava (IVC), enlargement of the diameter of the
PA, and straightening, bowing or paradoxal movement of
the interventricular septum, these parameters have been the
subject of several studies as a potential marker of RVD.
However, these studies show discrepancies regarding the
potential of these markers as an independent predictor of
both fatal and non-fatal adverse outcomes [42, 44–46].
Although, for instance, the diameter of the PA has long
been used as a parameter of RVD in echocardiography, Van
der Meer et al. did not find a significant relationship
between PA to ascending aorta diameter ratio and PE-
related mortality [35].
If and how these parameters can be used in a risk
stratification model has to be the subject of future
prospective research.
Thrombus load
As already stated, the clinical spectrum of PE and the large
differences in outcome are considered to be related to both
thrombus load and cardiopulmonary status. Because of its
excellent clot imaging, CTA can also be used for the
quantification of the thrombus load in the pulmonary
vascular tree, for which four different scoring systems have
been proposed. A detailed discussion of these individual
scoring systems is beyond the scope of this article. The
modified Walsh and the Miller scores, which are both
angiographic scores adapted to the needs of spiral CT,
quantify the severity of pulmonary obstruction [47]. Both
scores, however, do not differentiate between partial and
complete obstruction of a pulmonary vessel. The more
recent scores proposed by the groups of Qanadli and
Mastora, which were primarily developed for CTA, not only
give information about thrombus load, but also about the
degree of obstruction [48, 49].
Despite its excellent clot imaging, the literature shows
mixed results in the usefulness of the PA obstruction index
as a predictor of RVD and mortality. Qanadli et al. found
that a CTobstruction score of 40% or greater correlates well
with RV dilatation by identifying more than 90% of the
patients with PE and RV dilatation [49]. These results were
confirmed in the study of Van der Meer et al., reporting an
11.2-fold increased risk of dying of PE for patients with an
obstruction index of 40% or higher [35]. In a more recent
study of Bazeed et al. a significant difference in the PA
obstruction index of more than 50% between survivors and
non-survivors of PE was present [50]. On the contrary, no
association between clot burden and mortality was revealed
by others [42, 44, 46]. Therefore, based on the current
literature, there is insufficient support for a vascular
obstruction score to be used in a risk stratification system
of patients with PE.
Other biomarkers
New CT techniques: ECG-gated CTA and dual-source CT
Recent developments in CT might be able to further help us
in the risk stratification of PE. ECG-gated CTA gives the
possibility for dynamic and functional cardiac assessment
[51]. Information can be obtained about the ejection
fraction, RV/LV volumes ratio, RV wall motion abnormality,
Fig. 2 CTPA of a 31-year-old female patient who was reanimated. The
1-mm axial reconstructions demonstrate bilateral central pulmonary
emboli with dilatation of the main pulmonary artery (a) and massive
right-sided cardiac dilatation with compression of the left ventricle (b).
The patient died shortly after as a result of massive cerebral ischemia
Insights Imaging (2011) 2:705–715 709foramen ovale patency (right to left shunt), and intracardiac
thrombus[45, 52], information that is currently provided by
echocardiography. By using dedicated three-dimensional
software for post-processing, obtaining these measurements
does not have to be time-consuming, making it potentially
useful in the acute clinical setting. Dual-source CT can be
used in the diagnosis of PE in several ways. Using high-
pitch dual spiral protocols, the so-called flash technique, it
is possible to scan the complete chest in less than a second
[53], which is particularly helpful to obtain diagnostic
quality in dyspneic patients. It can also easily be used for
functional assessment of the heart using ECG gating. In
addition, by using the dual-energy technique, it not only
gives direct information on thrombus load, but also
functional information on lung perfusion can be obtained
at the same time [54, 55]. This perfusion information can be
Fig. 3 CTPA performed in a 22-
year-old male patient complain-
ing of progressive dyspnea and
chest pain, revealing extensive
pulmonary emboli including the
main pulmonary artery with
dilatation of the main pulmonary
artery (a, diameter 33 mm)
and the right side of the heart
(b). The wedge-shaped subpleu-
ral consolidation (c) is caused
by pulmonary infarction
(d, pulmonary window setting).
Because of the extensive load
and the right ventricular
dysfunction at CT, the patient
was admitted to the ICU for
thrombolytic treatment. The
patient became hypotensive
shortly after arrival but recov-
ered quickly after treatment. The
follow-up CTPA after 1 week
shows clearance of thrombus
from the main pulmonary artery
with normalization of its diame-
ter (e, diameter 25 mm) and
normalization of the right
ventricle. There is still extensive
thrombus present on both sides
710 Insights Imaging (2011) 2:705–715useful, as small subsegmental emboli, compared to large
non-occlusive emboli, can more easily result in complete
obstruction of the pulmonary vascular bed and therefore
may have a significant effect on the hemodynamic status.
More research in this area needs to be done to prove its
additional value in the risk stratification of PE.
Computer-assisted detection (CAD) software has been
developed for the assessment of CTA in PE. First, CAD can
be used as a second reader for improvement of the detection
of peripheral PE [56]. Second, CAD may also be utilized
for automated quantification of thrombus load [33], which
is likely to lead to a significant reduction of the assessment
time and therefore making evaluation of the thrombus load
better applicable in the clinical setting. The incorporation of
a CAD system was found to significantly improve
assessment of PE severity. This was accomplished by
increasing the observer’s sensitivity and correctly raising
the percentual embolic occlusion of the pulmonary arterial
bed. Consequently, this better accuracy of the severity
assessment resulted in improved agreement on the risk
stratification of PE patients [57].
Potential risk strategies
In patients with PE, risk stratification models can be used to
identify both patients who are either at high risk or at low
risk of an adverse outcome after PE. Based on evidence
currently available, the European Society of Cardiology
(ESC) has defined principle markers useful for risk
stratification in acute PE (Table 2)[ 3]. Of these, markers
of RVD and cardiac biomarkers are likely to be the most
attributable to a potential risk stratification system.
Several potential risk stratification models have been
proposed. In some of these recommended algorithms
markers of RVD and cardiac biomarkers were taken into
consideration [3, 5, 15, 58]. Some authors combined
cardiac biomarkers and echocardiography, selecting patients
initially based on levels of BNP or troponin and secondly
on signs of RVD on echocardiography [15]. In other
strategies, it is proposed that imaging techniques like CTA
or echocardiography should be used as a first step to
establish the presence of RVD in a selected group of
patients, namely those with an intermediate to high PESI
Clinical markers Shock
Hypotension
Markers of RVD RV dilatation, hypokinesis, or pressure overload on echocardiography
RV dilatation in CT
BNP of NT-proBNP elevation
Elevated right heart pressure at right heart catheterization
Markers of myocardial injury Cardiac troponins
Table 2 Prinicipal markers con-
sidered useful for risk stratifica-
tion in acute pulmonary
embolism [3]
RVD=right ventricular
dysfunction
RV=right ventricle
CT=computed tomography
BNP=brain natriuretic peptide
5
10 
20 
25 
40 
RVD + TnT/BNP
RVD – TnT/BNP
no RVD + TnT/BNP
no RVD – TnT/BNP
asymptomatic 
shock,      
hypo-
tension 
>30 
   7-10 
   5-8 
   3 
  <3 
    >1 
Estimated mortality (%) Estimated prevalence (%)
Fig. 4 The estimated prevalence and mortality of different risk factors in patients with pulmonary embolism (adapted from Becattini et al. 2008)
[5]. RVD=right ventricular dysfunction, TnT=troponin T, BNP=brain natriuretic peptide
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normal abnormal
normal
Hemodynamically 
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Establish diagnosis 
a
b
PE
RV function:
Echocardiography, MDCT, 
BNP levels
Markers of injury:
Troponin, H-FABP’s
ICU and/or 
thrombolysis
Outpatient treatment Medical ward
no risk 
factors
other risk factors
no bleeding risk
normal
normal
1 abnormal
1 abnormal
1 abnormal
1 abnormal
Hemodynamically 
stable 
Establish diagnosis 
PE
Cardiac biomarkers:
Troponin, BNP levels (H-
FABP’s)
RV function:
Echocardiography, MDCT
ICU and/or 
thrombolysis
Outpatient treatment Medical ward
other risk factors
no bleeding risk
no risk 
factors
712 Insights Imaging (2011) 2:705–715score and increased troponin levels [58]. Since CTA is the
first imaging modality of choice in the diagnosis of PE in
hemodynamically stable patients [33], additional informa-
tion on RVD is obtained simultaneously and can therefore
easily be incorporated in a risk stratification strategy. The
clinical relevance and therapeutic consequence of any of
these strategies, however, have so far not been evaluated in
prospective studies, and their clinical value, therefore,
remains uncertain.
Becattini et al. published a scheme in 2008 in which the
prevalence of different features in patients with PE
(asymptomatic, no RVD on ultrasound, RVD on ultrasound
± increased troponin levels, hypotension and shock) was
related to their mortality [5]. By introducing CT and the
cardiac biomarkers defined by the ESC [3] in this scheme,
we might be able to identify subgroups of hemodynami-
cally stable patients that are either at high or low risk of
both fatal and non-fatal adverse outcome (Fig. 4).
In the clinical management of hemodynamically stable
patients, there are several options. Depending on the risk
stratification, the management may range from outpatient
treatment to admission to intensive care unit (ICU) and/or
thrombolysis (Figs. 5a and b)[ 3, 59, 60]. There are currently
no data available on whether thrombolysis and/or observa-
tion in the ICU is the best treatment option for high-risk PE
patients, i.e., with RVD, in the hemodynamically stable
group. The results of an ongoing study on the benefit of
thrombolysis in this high-risk PE group, including the
patients that also have abnormal troponin levels (Clinical-
Trials.gov NCT 00639743), will provide data that can be
used in future risk stratification and treatment of this patient
group. As mentioned before, whether outpatient treatment in
low-risk patients is a good alternative to the initial
conventional in-hospital i.v. heparin treatment for at least
5 days is currently under investigation (OTPE trial).
We propose two different risk stratification models in
hemodynamically stable PE patients based on Becattini’s
proposed clinical management strategy and the revised
Becattini prevalence scheme (Fig. 4). In Becattini’s
management proposal based on risk stratification, markers
of dysfunction (ultrasound, MDCT, BNP levels) should be
assessed first in hemodynamically stable patients with
proven PE [5]. If normal, the patient can be admitted to a
medical ward. If at least one marker of dysfunction is
abnormal, markers of cardiac injury should be assessed
(troponin, H-FABPs). Only patients in whom these markers
are also abnormal should be admitted to the ICU.
The first proposed model (Fig. 5a) closely resembles
Becattini’s strategy. The main difference is the inclusion of
other risk factors such as bleeding risk, and treatment with
thrombolysis and outpatient treatment in the algorithm.
Outpatient treatment can be a good option if both RVD and
signs of myocardial injury are absent. In the second model
(Fig. 5b), the cardiac biomarkers troponin, BNP and/or
FABP are taken into consideration before assessing the
presence of RVD by either CT or echocardiography. In this
model, outpatient treatment can only be considered if the
cardiac biomarkers reveal no abnormalities. If these bio-
markers are abnormal, two options are left: admission to the
medical ward when signs of RVD are absent or admission to
the ICU in combination with thrombolysis if RVD is present.
As CT is the first imaging method of choice in the diagnosis
of acute PE and currently considered the gold standard for
PE, assessment of RV function on CT is a practical first step
and should be evaluated in every patient with PE at CT.
Cardiac echocardiography in general has a lower availability
and has no proven additional value once CT has been
performed. Laboratory testing including cardiac biomarkers
should be obtained in every patient with suspected PE or
acute cardiac disease. We think that this combination of CT
and blood tests is the easiest strategy, most time-efficient, and
probably most cost-effective. However, like the risk strate-
gies proposed by other authors, these strategies need further
prospective validation before they can be implemented in
clinical practice.
Summary
In the large group of normotensive patients with PE, there
seems to be a subgroup of patients with an increased risk of
an adverse, even lethal, outcome, which might benefit from
more aggressive therapy than the current standard therapy
with anticoagulants. Risk stratification is a commonly used
method to define subgroups of patients with either a high or
low risk of an adverse outcome. Clinical parameters,
biomarkers, or imaging markers of myocardial injury and
RVD have been suggested to play an important role in the
risk stratification of PE. In this overview we propose two
risk stratification models combining parameters that have
Fig. 5 a The clinical management of hemodynamically stable patients
in pulmonary embolism. After establishing the diagnosis of PE, RV
function should be determined, followed by the markers of myocardial
injury. If there are signs of RVD and an elevation of troponin or fatty
acid binding proteins, thrombolysis could be the next step. If there is
only RVD or an elevation in the markers of myocardial injury, then the
patient could be admitted to the medical ward. Outpatient treatment is
the option in the absence of RVD or signs of myocardial injury. b
After establishing the diagnosis of PE, the cardiac biomarkers are first
taken into consideration. Outpatient treatment can only be considered
if the cardiac biomarkers reveal no abnormalities. If these biomarkers
are abnormal, RV function should be monitored. In case of RVD, only
two options are left: admission to the medical ward in the absence of
RVD or admission to ICU in combination with thrombolysis in the
presence of RVD. PE=pulmonary embolism, BNP=brain natriuretic
peptides, H-FABP’s=fatty acid binding proteins, RV=right ventricle,
RVD=right ventricular dysfunction, MDCT=multidetector computed
tomography, ICU=intensive care unit
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Insights Imaging (2011) 2:705–715 713already been shown to be independent predictors of adverse
outcomes, namely markers of RVD, either assessed with
CT, echocardiography or BNP, and cardiac biomarkers of
ischemia to stratify patients into those that should be
admitted to the ICU and/or be given thrombolysis, admitted
to the medical ward, or can be safely treated at home with
anticoagulant therapy. Like the risk strategies previously
proposed by other authors, these strategies need further
prospective validation before they can be implemented in
clinical practice. New developments in CT, such as ECG-
gated CTA and dual-source CT, have the potential to further
help us in the risk stratification of PE as these new
techniques give us the possibility to obtain both functional
and dynamic information at the same time in patients with
suspected PE.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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